Oyogist has learned that AstraZeneca has been cleared by the European Commission for its proposed acquisition of Alexion Pharmaceuticals, Inc.
According to sources, the approval follows clearances in the United States, Japan and other countries.
Some time ago in 2020, AstraZeneca agreed to buy Alexion for 175 dollars per share in cash and stock, valuing the Boston-based company at 39 billion dollars.
AstraZeneca said the proposed acquisition will enhance its scientific presence in immunology by adding Alexion’s innovative complement-technology platform and an extensive pipeline.
